Literature DB >> 7826210

Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells.

C Delenda1, M P Frenkiel, V Deubel.   

Abstract

We constructed a recombinant baculovirus encoding a dengue (DEN)-2 virus envelope glycoprotein truncated of 102 amino acids (aa) at its C-terminus (D2E delta 102). The production, processing and transportation of the recombinant protein in baculovirus-infected Spodoptera frugiperda (Sf9) cells and its immunogenic properties in mice were compared to those of a previously characterized recombinant DEN-2 E-protein with a 71aa C-terminal truncation (D2E delta 71). Both proteins were transported through the Golgi complex and their N-oligosaccharides of the high mannose type were processed to the complex mannose type. D2E delta 102 transited to the plasma membrane and was secreted whereas D2E delta 71 presumably remained associated with the plasma membrane. The reactivities of the recombinant proteins with neutralizing monoclonal antibodies were similar. Both intracellular and extracellular D2E delta 102 induced neutralizing antibodies in mice and were thus immunogenic. The level of protective immunity to DEN-2 virus encephalitis challenge in mice vaccinated with intracellular D2E delta 102 (80%, p < 0.01) was lower than that induced with D2E delta 71 (90%, P < 0.001). Sixty-eight percent (P < 0.001) of mice vaccinated with 5 micrograms of extracellular D2E delta 102 protein were protected against lethal challenge.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826210     DOI: 10.1007/bf01309465

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  24 in total

1.  Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein.

Authors:  F Megret; J P Hugnot; A Falconar; M K Gentry; D M Morens; J M Murray; J J Schlesinger; P J Wright; P Young; M H Van Regenmortel
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

2.  Purification of native dengue-2 viral proteins and the ability of purified proteins to protect mice.

Authors:  R Feighny; J Burrous; J McCown; C Hoke; R Putnak
Journal:  Am J Trop Med Hyg       Date:  1992-10       Impact factor: 2.345

3.  From the World Health Organization. Development of dengue and Japanese encephalitis vaccines.

Authors:  W E Brandt
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

4.  Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses.

Authors:  Y S Hahn; E M Lenches; R Galler; C M Rice; J Dalrymple; J H Strauss
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  Low pH-induced cell fusion in flavivirus-infected Aedes albopictus cell cultures.

Authors:  V B Randolph; V Stollar
Journal:  J Gen Virol       Date:  1990-08       Impact factor: 3.891

6.  Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus.

Authors:  B T Zhao; G Prince; R Horswood; K Eckels; P Summers; R Chanock; C J Lai
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

7.  Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis.

Authors:  Y M Zhang; E P Hayes; T C McCarty; D R Dubois; P L Summers; K H Eckels; R M Chanock; C J Lai
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

8.  endo-beta-N-acetylglucosaminidase F: endoglycosidase from Flavobacterium meningosepticum that cleaves both high-mannose and complex glycoproteins.

Authors:  J H Elder; S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

Review 9.  Pathogenesis of dengue: challenges to molecular biology.

Authors:  S B Halstead
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

10.  Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue.

Authors:  V Deubel; R M Kinney; J J Esposito; C B Cropp; A V Vorndam; T P Monath; D W Trent
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

View more
  7 in total

1.  Antibody recognition of the dengue virus proteome and implications for development of vaccines.

Authors:  Stefan Fernandez; Emily D Cisney; Alexander P Tikhonov; Barry Schweitzer; Robert J Putnak; Monika Simmons; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

2.  Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form.

Authors:  S L Allison; K Stadler; C W Mandl; C Kunz; F X Heinz
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

3.  Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins.

Authors:  Stephan T Kudlacek; Lakshmanane Premkumar; Stefan W Metz; Ashutosh Tripathy; Andrey A Bobkov; Alexander Matthew Payne; Stephen Graham; James A Brackbill; Michael J Miley; Aravinda M de Silva; Brian Kuhlman
Journal:  J Biol Chem       Date:  2018-04-20       Impact factor: 5.157

4.  Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies.

Authors:  J Groen; P Koraka; J Velzing; C Copra; A D Osterhaus
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

5.  A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

Authors:  Nathalie Bonafé; Joseph A Rininger; Richard G Chubet; Harald G Foellmer; Stacey Fader; John F Anderson; Sandra L Bushmich; Karen Anthony; Michel Ledizet; Erol Fikrig; Raymond A Koski; Paul Kaplan
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

6.  Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.

Authors:  David E Clements; Beth-Ann G Coller; Michael M Lieberman; Steven Ogata; Gordon Wang; Kent E Harada; J Robert Putnak; John M Ivy; Michael McDonell; Gary S Bignami; Iain D Peters; Julia Leung; Carolyn Weeks-Levy; Eileen T Nakano; Tom Humphreys
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

Review 7.  Vaccines for viral and parasitic diseases produced with baculovirus vectors.

Authors:  Monique M van Oers
Journal:  Adv Virus Res       Date:  2006       Impact factor: 9.937

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.